STOCK TITAN

Mural Oncology PLC - MURA STOCK NEWS

Welcome to our dedicated page for Mural Oncology PLC news (Ticker: MURA), a resource for investors and traders seeking the latest updates and insights on Mural Oncology PLC stock.

Mural Oncology PLC (MURA) is a clinical-stage biotech company pioneering engineered cytokine therapies for cancer treatment. This page aggregates official announcements, clinical trial updates, and strategic developments related to their innovative immuno-oncology pipeline.

Investors and researchers will find timely updates on key programs including nemvaleukin (IL-2 fusion protein), IL-18, and IL-12 therapies. Content spans regulatory milestones, partnership announcements, financial disclosures, and scientific presentations - all essential for understanding the company's progress in redefining cytokine-based cancer treatments.

Our curated news collection enables efficient tracking of material events including clinical trial initiations, data readouts, and intellectual property developments. The resource is particularly valuable for monitoring advancements in protein-engineered therapies designed to enhance antitumor immunity while reducing systemic toxicity.

Bookmark this page for consolidated access to Mural Oncology's latest developments in immuno-oncology research and clinical translation. Check regularly for updates on novel therapeutic approaches that combine cytokine biology with precision engineering.

Rhea-AI Summary

Mural Oncology (Nasdaq: MURA) has granted equity incentives to five new employees as inducement awards. The grants include 23,500 stock options with an exercise price of $3.46 per share and 12,500 restricted stock units. The stock options have a ten-year term and vest over four years, with 25% vesting after one year and 6.25% quarterly thereafter. The restricted stock units vest 25% annually over four years. These grants were made under the company's 2024 Inducement Stock Option and Incentive Plan in accordance with Nasdaq Rule 5635(c)(4).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.76%
Tags
none
-
Rhea-AI Summary

Mural Oncology plc (Nasdaq: MURA) announced three upcoming poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) from November 6-10, 2024, in Houston. The presentations will cover:

1. Tumor microenvironment pharmacodynamic data from the phase 1/2 ARTISTRY-3 study, evaluating less frequent dosing of nemvaleukin, Mural's engineered interleukin-2 (IL-2).

2. Preclinical efficacy and immune activity data for half-life extended IL-18 fusion proteins.

3. Modulation of IL-12p70 exposure and activity following sequential administration of tumor-targeted self-assembling split IL-12 subunits.

These presentations showcase Mural's progress in developing novel engineered cytokine therapies for cancer treatment, including their IL-2, IL-18, and IL-12 research programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
conferences clinical trial
-
Rhea-AI Summary

Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company, has announced the granting of inducement awards to three newly hired employees on October 1, 2024. The awards, granted under the company's 2024 Inducement Stock Option and Incentive Plan, include:

1. Non-statutory stock options to purchase 28,525 ordinary shares at an exercise price of $3.13 per share, equal to the closing price on October 1, 2024. These options have a ten-year term and vest over four years.

2. Restricted stock units for 14,975 ordinary shares, vesting over four years at 25% per year.

These grants are in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the employees' continued service with the company through applicable vesting dates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
none
Rhea-AI Summary

Mural Oncology plc (Nasdaq: MURA) is hosting a virtual Investor Day to highlight progress in its late-stage clinical trials. Key data readouts for nemvaleukin are expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma. The company will provide new insights into trial design and statistical assumptions for ARTISTRY-7 and ARTISTRY-6 studies.

ARTISTRY-7, a phase 3 trial for platinum-resistant ovarian cancer, has completed enrollment with 456 patients. The study's interim analysis is estimated to occur by late Q4 2024 or early Q1 2025, with data readout expected in late Q1 or early Q2 2025.

ARTISTRY-6, cohort 2, a potentially registrational study for mucosal melanoma, has completed enrollment with 92 patients. Top-line readout is anticipated in Q2 2025.

Mural also plans to submit an IND for its IL-18 program in Q4 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.31%
Tags
none
-
Rhea-AI Summary

Mural Oncology plc (Nasdaq: MURA) has announced the appointment of Sachiyo Minegishi to its board of directors, effective September 20, 2024. Minegishi will serve as Chair of the Audit Committee and join the Nominating and Corporate Governance Committee. With over 20 years of industry experience, she brings expertise in corporate strategy, finance, development, and commercialization.

Currently the Chief Operating Officer at Rectify Pharmaceuticals, Minegishi has previously held leadership roles at Akouos, bluebird bio, Human Genome Sciences, Genzyme, and Amgen. Her appointment comes as Mural Oncology prepares for key milestones, including candidate nominations for IL-18 and IL-12 programs this year and readouts in two potentially registrational studies of nemvaleukin in the first half of 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
management
-
Rhea-AI Summary

Mural Oncology plc (Nasdaq: MURA) has announced its first Virtual Investor Day, scheduled for September 26, 2024, at 10 a.m. ET. The event will provide clinical insights and updates on the company's late-stage candidate, nemvaleukin alfa, an engineered IL-2 therapy. Mural remains on track to deliver key data readouts from potentially registrational trials in platinum-resistant ovarian cancer and mucosal melanoma in 1H 2025.

The Investor Day will feature presentations from Mural's leadership, including CEO Caroline Loew and CMO Vicki Goodman, as well as expert clinicians. They will discuss the trial design, clinical proof of concept, and unmet needs in target cancer types. Additionally, Mural will provide an overview of its IL-18 pipeline program.

The event aims to showcase Mural's progress in developing novel, engineered cytokine therapies for various cancers. Interested parties can register for the webcast at ir.muraloncology.com/events-and-presentations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
conferences
Rhea-AI Summary

Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company, has granted stock options and restricted stock units to a newly hired employee. The company issued non-statutory stock options to purchase 21,500 ordinary shares and restricted stock units for 11,500 ordinary shares. These grants were made under Mural's 2024 Inducement Stock Option and Incentive Plan, in compliance with Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $3.16 per share, equal to the closing price on September 3, 2024. They have a ten-year term and vest over four years, with 25% vesting after one year and 6.25% quarterly thereafter. The restricted stock units also vest over four years, with 25% vesting annually. Both grants are subject to continued employment and specific award agreements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.59%
Tags
none
-
Rhea-AI Summary

Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company, has announced its participation in two upcoming investor conferences. The company, which develops novel engineered cytokine therapies for cancer patients, will be represented by key management team members at these events:

1. Morgan Stanley 22nd Annual Global Healthcare Conference on September 6 at 1:50 p.m. ET, featuring a fireside chat with CEO Caroline Loew, Ph.D., Chief Medical Officer Vicki Goodman, MD, and CFO Adam Cutler.

2. H.C. Wainwright 26th Annual Global Investment Conference on September 11 at 9:30 a.m. ET, where CEO Caroline Loew, Ph.D. will give a presentation.

Webcasts of both presentations will be available on the company's investor relations website. The management team will also be available for one-on-one meetings during these conferences.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.24%
Tags
conferences
-
Rhea-AI Summary

Mural Oncology (Nasdaq: MURA) reported Q2 2024 financial results and provided a pipeline update. Key highlights include:

Financial Position: Cash, cash equivalents, and marketable securities stood at $204.7 million as of June 30, 2024. The company reaffirms its cash runway into Q4 2025.

Pipeline Progress: Mural is on track to report readouts from two late-stage clinical trials of its lead asset, nemvaleukin alfa, in 1H 2025. The company presented data on less frequent dosing of nemvaleukin at ASCO in June. Candidate nominations for IL-18 and IL-12 programs are expected later this year.

Financial Results: R&D expenses decreased to $27.5 million in Q2 2024 from $42.5 million in Q2 2023. G&A expenses increased to $6.7 million from $4.7 million. Net loss narrowed to $31.6 million from $50.2 million year-over-year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
Rhea-AI Summary

Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company, announced on August 2, 2024, that it granted stock options and restricted stock units to a newly hired employee on August 1. The grants include:

1. Non-statutory stock options to purchase 13,000 ordinary shares
2. Restricted stock units for 7,000 ordinary shares

These grants were made under the company's 2024 Inducement Stock Option and Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $3.48 per share, equal to the closing price on August 1, 2024. They have a ten-year term and vest over four years. The restricted stock units also vest over four years, with 25% vesting annually.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.47%
Tags
none
Mural Oncology PLC

Nasdaq:MURA

MURA Rankings

MURA Stock Data

41.69M
16.95M
1.62%
60.66%
2.09%
Biotechnology
Pharmaceutical Preparations
Link
Ireland
DUBLIN 2